C&L: Gallagher tapped for top Metastatix post

Carol Gallagher, formerly with Anadys Pharmaceuticals, has been named CEO of Metastatix.

Pipex Pharmaceuticals has appointed David A. Newsome, M.D. as chief scientific officer.

Thomas, McNerney & Partners announced that Eric Aguiar, M.D., has joined as a partner in the firm's Connecticut office. Jason Brown, Ph.D. joined the firm as an associate in the San Francisco office.

Daniel Murch, a former executive with GlaxoSmithKline, has joined startup CeNeRx BioPharma as its executive vice president for research and development as well as chief medical officer

EntreMed announced that Kenneth W. Bair, Ph.D. has been appointed its senior vice president, research and development.

Prof. Michel Klein has been named chief scientific officer at AMVAC.

Access Genetics has appointed Paul J. Hoedeman as its CFO and Elizabeth A. Skinneras VP--legal, quality and regulatory.

Mark Iwicki has been appointed to the newly created position of executive vice president and chief commercial officer at Sepracor. Jay Smith has been appointed to the position of senior vice president of sales, Dean Giovanniello has been appointed to the position of vice president of marketing and Thomas Hoover has been appointed to the position of vice president, new products planning.

ViRexx Medical Corp. announced that Erich Bam has been appointed as interim COO.

Burnham Institute for Medical Research has appointed Cyril Doucet as vice president, operations and administration for Burnham at Lake Nona in Orlando.

MicroIslet announced today that Amaresh Basu, Ph.D. has been named vice president, research and development.

Velcura Therapeutics has named Jeffrey N. Fellows vice president of regulatory affairs.

Pharsight has hired Lars Lindbom, Ph.D., as a senior associate scientist in its Strategic Consulting Services group, based in Europe.

Helix BioPharma announced that Jerome F. McElroy has resigned as chairman and a director of the company to pursue his retirement interests.

Avicena Group has named CEO Belinda Tsao-Nivaggioli, Ph.D., to the additional role of chairman of the board.

BrainStorm Cell Therapeutics has appointed Rasheda Ali, daughter of boxer and long time Parkinson's sufferer Muhammad Ali, as a member of the company's advisory board.

Stem Cell Therapeutics has named Scott Tannas to the board of directors.

Solstice Neurosciences has appointed Dennis L. Smith to its board of directors.

Alan Walton, the co-founder of Avalon Pharmaceuticals, has resigned from the board of directors.

Alchemia has created an SAB which will be chaired by Dr. Tracie Ramsdale, one of Alchemia's founders and former CEO.

Synosia Therapeutica has created an SAB and named J.D. Fitzgerald, FRCP, chairman.

Oxford Genome Sciences has strengthened its Scientific Advisory Board with the appointment of Sir Walter Bodmer.

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.